Journey Medical: A Small Pharma With A Large Growth Opportunity

Journey Medical ( DERM ) has a new winning product in Emrosi, and it's gaining traction with dermatologists and patients as more people get experience with the treatment. The opportunity is still relatively early, with prescription growth. DERM leverages existing infrastructure for Emrosi, achieving high gross margins and operating leverage, pushing toward sustainable profitability. Conservative growth assumptions and a 4x EV/Sales multiple yield a $15 target price, implying 109% upside over three years. Risks include payer friction and potential generic competition, but DERM’s valuation and growth profile offer an attractive risk/reward.